Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;20(1):87-90.
doi: 10.1016/j.gde.2009.11.002. Epub 2009 Dec 16.

Targeting the PI3K signaling pathway in cancer

Kwok-Kin Wong  1 , Jeffrey A Engelman, Lewis C Cantley
Affiliations
Review

Targeting the PI3K signaling pathway in cancer

Kwok-Kin Wong et al. Curr Opin Genet Dev. 2010 Feb.

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of how the PI3K-AKT and MEK-ERK pathways regulate apoptosis in EGFR driven cancers.
See this image and copyright information in PMC

References

    1. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–1657. - PubMed
    1. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–562. - PubMed
    1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–619. - PubMed
    1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501. - PubMed
    1. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3:1221–1224. - PubMed

MeSH terms